0000921895-23-001753.txt : 20230728
0000921895-23-001753.hdr.sgml : 20230728
20230728174210
ACCESSION NUMBER: 0000921895-23-001753
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230726
FILED AS OF DATE: 20230728
DATE AS OF CHANGE: 20230728
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NATAN DAVID
CENTRAL INDEX KEY: 0001253108
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13341
FILM NUMBER: 231124345
MAIL ADDRESS:
STREET 1: 11190 BISCAYNE BLVD
CITY: MIAMI
STATE: FL
ZIP: 33181
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000910267
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943171940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 OYSTER POINT BLVD
STREET 2: SUITE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6502444990
MAIL ADDRESS:
STREET 1: 400 OYSTER POINT BLVD
STREET 2: SUITE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form413531nat_07282023.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-26
0
0000910267
TITAN PHARMACEUTICALS INC
TTNP
0001253108
NATAN DAVID
11190 BISCAYNE BLVD
MIAMI
FL
33181
1
0
0
0
0
Common Stock
2023-07-26
4
A
0
50000
0
A
50000
D
Option to Purchase Common Stock
1.52
2023-06-29
4
A
0
25000
0
A
2022-08-15
Common Stock
25000
25000
D
Option to Purchase Common Stock
1.31
2023-06-29
4
A
0
100000
0
A
2022-09-15
Common Stock
100000
100000
D
The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.
The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.
/s/ David Natan
2023-07-28